NASDAQ:MGTA - Magenta Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.60
  • Forecasted Upside: 164.86 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.11 (-1.46%)

This chart shows the closing price for MGTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Magenta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGTA

Analyst Price Target is $19.60
▲ +164.86% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Magenta Therapeutics in the last 3 months. The average price target is $19.60, with a high forecast of $22.00 and a low forecast of $17.00. The average price target represents a 164.86% upside from the last price of $7.40.

This chart shows the closing price for MGTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Magenta Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/22/2021B. RileyLower Price TargetHold ➝ Buy$21.00 ➝ $19.00High
6/29/2021Cantor FitzgeraldInitiated CoverageOverweight$20.00High
6/14/2021BTIG ResearchInitiated CoverageBuy$20.00Medium
5/18/2021B. RileyInitiated CoverageBuy$21.00High
5/13/2021MizuhoBoost Price TargetBuy$16.00 ➝ $17.00High
1/28/2021MizuhoInitiated CoverageBuy$16.00High
1/6/2021MizuhoInitiated CoverageBuy$16.00N/A
10/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
8/13/2020WedbushReiterated RatingOutperform$22.00Low
6/12/2020WedbushReiterated RatingBuy$22.00Medium
6/8/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$15.00High
1/13/2020CowenReiterated RatingBuyLow
12/9/2019CowenReiterated RatingBuyHigh
12/6/2019BTIG ResearchInitiated CoverageBuy$20.00Medium
12/6/2019The Goldman Sachs GroupReiterated RatingNeutral$18.00High
11/13/2019CowenReiterated RatingBuyHigh
11/6/2019CowenReiterated RatingBuyMedium
8/8/2019CowenReiterated RatingBuyMedium
5/10/2019WedbushReiterated RatingOutperform$22.00High
3/24/2019The Goldman Sachs GroupDowngradeBuy ➝ Neutral$17.00 ➝ $16.00High
3/14/2019Raymond JamesInitiated CoverageOutperform ➝ OutperformHigh
7/16/2018CowenInitiated CoverageOutperformHigh
7/16/2018JPMorgan Chase & Co.Initiated CoverageOverweight$18.00High
7/16/2018The Goldman Sachs GroupInitiated CoverageBuy$18.00High
7/16/2018WedbushInitiated CoverageOutperform$22.00High
(Data available from 7/25/2016 forward)
Magenta Therapeutics logo
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent prophylaxis of graft-versus-host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, evaluate potential utility of MGTA-117 for conditioning of patients receiving one or more investigational lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $7.40
Low: $7.26
High: $7.74

50 Day Range

MA: $10.49
Low: $7.40
High: $12.70

52 Week Range

Now: $7.40
Low: $6.03
High: $14.20


446,150 shs

Average Volume

248,952 shs

Market Capitalization

$432.97 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Magenta Therapeutics?

The following Wall Street analysts have issued research reports on Magenta Therapeutics in the last twelve months: B. Riley, BTIG Research, Cantor Fitzgerald, JPMorgan Chase & Co., Mizuho, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for MGTA.

What is the current price target for Magenta Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Magenta Therapeutics in the last year. Their average twelve-month price target is $19.60, suggesting a possible upside of 164.9%. Wedbush has the highest price target set, predicting MGTA will reach $22.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $17.00 for Magenta Therapeutics in the next year.
View the latest price targets for MGTA.

What is the current consensus analyst rating for Magenta Therapeutics?

Magenta Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MGTA will outperform the market and that investors should add to their positions of Magenta Therapeutics.
View the latest ratings for MGTA.

What other companies compete with Magenta Therapeutics?

How do I contact Magenta Therapeutics' investor relations team?

Magenta Therapeutics' physical mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company's listed phone number is 857-242-0170 and its investor relations email address is [email protected] The official website for Magenta Therapeutics is